The Wolverine stack is a pre-mixed vial of BPC-157 and TB-500 sold for injury recovery, and it is not proven: no human or animal study has tested the two together. Neither peptide is FDA-approved, and the FDA moved both off its Category 2 list in April 2026 without clearing either for compounding.[8]
Search any recovery forum and you will run into the “Wolverine stack”: a single vial that pairs BPC-157 with TB-500, named for the comic-book character who heals from anything. It is pitched as a one-injection shortcut to faster tendon, muscle and joint repair. Before anyone treats that pitch as settled science, it is worth taking the blend apart — what is actually in it, why people combine the two, and how much of the “heals everything” promise survives contact with the published literature.
What's in the Wolverine stack?
The product is straightforward in concept: a vial of lyophilized powder containing both peptides at a fixed ratio, reconstituted with bacteriostatic water and self-injected subcutaneously. BPC-157 is a synthetic 15-amino-acid sequence; TB-500 is a fragment marketed as the actin-binding peptide thymosin beta-4. Sold separately they are the two best-known “healing peptides” in the recovery world; sold together as a blend, they are marketed as a convenience — one vial, one injection, both compounds. The convenience is real. Whether the pairing does anything the two would not do alone is the open question.
The theory behind combining them
The case for the stack is built entirely on mechanism, and on paper it is a tidy story. BPC-157 is studied for vascular and cytoprotective effects: in laboratory work its therapeutic potential has been linked to activation and up-regulation of the VEGFR2 receptor, a central switch in the growth of new blood vessels.[2] Reviewers of the preclinical literature describe a peptide that appears to accelerate the healing of damaged tendon, ligament and muscle in rodent models, partly by encouraging blood-vessel formation and connective-tissue activity at the wound.[1] TB-500, meanwhile, is built around a different job: thymosin beta-4 binds and sequesters G-actin monomers, regulating the cytoskeleton and, downstream, the migration of repair cells into injured tissue.[4] Stack-advocates put those two ideas side by side — build the supply line with one peptide, move the repair crew with the other — and conclude the effects must be complementary. It is a plausible hypothesis. It is not a finding.
Is the Wolverine stack proven? Zero evidence for the combination
Here is the part the marketing skips. There is no published human trial of a BPC-157 and TB-500 combination for any indication, nor a controlled preclinical study isolating a synergistic effect of the pair over either compound used alone. The two molecules have never been formally tested together as the “Wolverine stack.” Everything offered as support for the blend is really evidence about the individual peptides — and even that evidence is thin where it matters. A 2025 narrative review of BPC-157 for musculoskeletal healing concluded that, despite the intriguing animal data, the absence of controlled human trials and an unregulated supply chain mean it cannot be recommended for injury.[3] The credible human data for thymosin beta-4 comes from a Phase 2 randomized trial — in severe dry-eye disease, using an eye drop, not an injection for athletic recovery.[5] Its repair work in stroke and brain-injury models remains animal research.[6] When you combine two compounds that are each individually unproven for recovery in humans, you do not average two bodies of evidence; you multiply the uncertainty. The claimed synergy is an inference layered on top of preclinical inference. The same applies to the Glow and KLOW blends, which add GHK-Cu (and, in KLOW, KPV) to this pair.
Swipe to see all columns
| The stack’s claim | What actually exists | Tested as a blend? |
|---|---|---|
| BPC-157 builds new blood supply to the injury | VEGFR2 / angiogenesis findings in lab models | No |
| TB-500 moves repair cells into the tissue | Actin-sequestration biology; animal repair data | No |
| Combined, they heal faster than either alone | No combination study, human or animal | No |
| A pre-mixed vial is the convenient way to do it | Fixed ratio you cannot adjust; unregulated product | No |
The practical problems with a pre-mixed vial
Even setting the evidence question aside, a fixed-ratio blend creates problems a single-peptide vial does not. You inherit whatever ratio the seller chose, with no way to titrate one component independently or stop one while continuing the other — so if you react to something, you cannot tell which peptide caused it. Reconstitution is the same arithmetic as any lyophilized peptide (covered in our reconstitution guide and the peptide reconstitution calculator), but a blend means a single dosing decision now governs two compounds at once. And the supply itself is unregulated: these are research-grade products, typically labeled “for research use only,” not manufactured to pharmaceutical standards. With two active ingredients in one vial there is more surface area for contamination, mislabeling and dose error, not less.
Is the Wolverine stack legal? Where the FDA stands
Neither BPC-157 nor TB-500 is approved by the FDA for any use. Both had been placed in Category 2 of the FDA's interim compounding policy, its list of bulk substances that may present significant safety risks. After the nominations were withdrawn, the FDA moved both to its “nominated but withdrawn” list (page current as of April 22, 2026), noting for each a possible risk of immune reactions and limited or no human safety data.[8] That move is not an approval or a clearance: neither peptide is on the 503A bulks list, which is what a pharmacy needs to compound a drug from a bulk substance.
On July 23, 2026, the FDA's Pharmacy Compounding Advisory Committee discussed adding BPC-157 (for ulcerative colitis) and TB-500 (for wound healing) to that list,[9] and voted 8-6, with 1 abstention, to recommend each one.[10] The vote is advisory: the FDA must still decide whether to accept it and then complete notice-and-comment rulemaking before pharmacies could compound either peptide.[10] Even then, a listing would cover each peptide for its named use, not a pre-mixed recovery blend. Vials sold online as “research use only” sit outside all of this.
Read the components, not the bundle
The honest way to evaluate this product is to ignore the bundle and judge each peptide on its own record, then remember that combining them adds an extra untested step. Our standalone reviews lay out where each one actually stands: the BPC-157 evidence review walks through its deep rodent literature and absence of human trials, the TB-500 and thymosin beta-4 review separates the real dry-eye data from the recovery hype, and the BPC-157 versus TB-500 comparison sets the two molecules directly against each other. None of those pages can tell you the blend works, because no study can.
The honest bottom line
The Wolverine stack is a marketing construct wrapped around a genuinely interesting mechanistic idea. BPC-157 and TB-500 do act on different and arguably complementary parts of the repair process, and that is exactly why the pairing sells. But complementary on a whiteboard is not the same as synergistic in a person, and the entire combination rests on preclinical biology plus anecdote with no trial underneath it. Popular is not the same as proven. Until someone actually studies the two together in humans, the safest reading is the plain one: it is two unregulated, unproven recovery peptides in a single convenient vial — convenient, banned in sport, and no better evidenced than either component alone.
